Clinical Pharmacokinetics and Pharmacodynamics of Naloxone.

Garfield E. The 1982 John Scott Award goes to Jack Fishman and Harold Blumberg for synthesis and investigations on naloxone. Essay Inf Sci. 1983;6:121–30.

Foldes FF, Duncalf D, Kuwabara S. The respiratory, circulatory, and narcotic antagonistic effects of nalorphine, levallorphan, and naloxone in anaesthetized subjects. Can Anaesth Soc J. 1969;16(2):151–61.

pubmed: 5773493 doi: 10.1007/BF03005795

Foldes FF, Lunn JN, Moore J, Brown IM. N-Allylnoroxy-morphone: a new potent narcotic antagonist. Am J Med Sci. 1963;245:23–30.

pubmed: 13945736

Skolnick P. Treatment of overdose in the synthetic opioid era. Pharmacol Ther. 2022;233: 108019.

pubmed: 34637841 doi: 10.1016/j.pharmthera.2021.108019

Strang J, McDonald R, Campbell G, Degenhardt L, Nielsen S, Ritter A, et al. Take-home naloxone for the emergency interim management of opioid overdose: the public health application of an emergency medicine. Drugs. 2019;79(13):1395–418.

pubmed: 31352603 pmcid: 6728289 doi: 10.1007/s40265-019-01154-5

Stam NC, Cogger S, Schumann JL, Weeks A, Roxburgh A, Dietze PM, et al. The onset and severity of acute opioid toxicity in heroin overdose cases: a retrospective cohort study at a supervised injecting facility in Melbourne, Australia. Clin Toxicol. 2022;6:1–8.

Strang J, Darke S, Hall W, Farrell M, Ali R. Heroin overdose: the case for take-home naloxone. BMJ. 1996;312(7044):1435–6.

pubmed: 8664611 pmcid: 2351168 doi: 10.1136/bmj.312.7044.1435

Strang J. Take-home naloxone and the prevention of deaths from heroin overdose: pursuing strong science, fuller understanding, greater impact. Eur Addict Res. 2022;28(3):161–75.

pubmed: 34963112 doi: 10.1159/000519939

Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand. 2002;46(7):759–70.

pubmed: 12139528 doi: 10.1034/j.1399-6576.2002.460702.x

Dale O. Ethical issues and stakeholders matter. Addiction. 2016;111(4):587–9.

pubmed: 26995170 doi: 10.1111/add.13267

Strang J, McDonald R, Tas B, Day E. Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures? Addiction. 2016;111(4):574–82.

pubmed: 26840916 doi: 10.1111/add.13209

Krieter PA, Chiang CN, Gyaw S, McCann DJ. Comparison of the pharmacokinetic properties of naloxone following the use of FDA-approved intranasal and intramuscular devices versus a common improvised nasal naloxone device. J Clin Pharmacol. 2019;59(8):1078–84.

pubmed: 30861160 pmcid: 6606390 doi: 10.1002/jcph.1401

Olofsen E, van Dorp E, Teppema L, Aarts L, Smith TW, Dahan A, et al. Naloxone reversal of morphine- and morphine-6-glucuronide-induced respiratory depression in healthy volunteers: a mechanism-based pharmacokinetic-pharmacodynamic modeling study. Anesthesiology. 2010;112(6):1417–27.

pubmed: 20461002 doi: 10.1097/ALN.0b013e3181d5e29d

van Dorp E, Yassen A, Sarton E, Romberg R, Olofsen E, Teppema L, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology. 2006;105(1):51–7.

pubmed: 16809994 doi: 10.1097/00000542-200607000-00012

Yassen A, Olofsen E, Romberg R, Sarton E, Teppema L, Danhof M, et al. Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther. 2007;81(1):50–8.

pubmed: 17185999 doi: 10.1038/sj.clpt.6100025

Strang J, McDonald R, Alqurshi A, Royall P, Taylor D, Forbes B. Naloxone without the needle—systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal. Drug Alcohol Depend. 2016;163:16–23.

pubmed: 26996745 doi: 10.1016/j.drugalcdep.2016.02.042

Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, et al. Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose. J Clin Pharmacol. 2016;56(10):1243–53.

pubmed: 27145977 doi: 10.1002/jcph.759

McDonald R, Danielsson Glende O, Dale O, Strang J. International patent applications for non-injectable naloxone for opioid overdose reversal: exploratory search and retrieve analysis of the Patent Scope database. Drug Alcohol Rev. 2018;37(2):205–15.

pubmed: 28597483 doi: 10.1111/dar.12571

Dale O. Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults. Expert Opin Drug Metab Toxicol. 2022;18(3):203–17.

pubmed: 35500297 doi: 10.1080/17425255.2022.2072728

Lewenstein M, Fishman J, inventors; Moprhine derivate. USA patent 3254088; 1966.

Blumberg H, Dayton HB, George M, Rapaport DN. N-allylnoroxynorphone; a potent narcotic antagonist. Fedn Proc Fedn Am Soc. 1961;20:311.

Blumberg H, Dayton HB, Wolf PS. Counteraction of narcotic antagonist analgesics by the narcotic antagonist naloxone. Proc Soc Exp Biol Med. 1966;123(3):755–8.

pubmed: 4381176 doi: 10.3181/00379727-123-31595

WHO. The use of essential drugs. Technical report series. [cited 19th December 2022] 1983. https://www.who.int/publications/i/item/9241206853 .

McNicholas LF, Martin WR. New and experimental therapeutic roles for naloxone and related opioid antagonists. Drugs. 1984;27(1):81–93.

pubmed: 6319107 doi: 10.2165/00003495-198427010-00004

Sutar R, Sahu S. Pharmacotherapy for dissociative disorders: a systematic review. Psychiatry Res. 2019;281: 112529.

pubmed: 31470213 doi: 10.1016/j.psychres.2019.112529

Valbrun LP, Zvonarev V. The opioid system and food intake: use of opiate antagonists in treatment of binge eating disorder and abnormal eating behavior. J Clin Med Res. 2020;12(2):41–63.

pubmed: 32095174 pmcid: 7011935 doi: 10.14740/jocmr4066

Springborg AD, Jensen EK, Kreilgaard M, Petersen MA, Papathanasiou T, Lund TM, et al. High-dose naloxone: effects by late administration on pain and hyperalgesia following a human heat injury model. A randomized, double-blind, placebo-controlled, crossover trial with an enriched enrollment design. PLoS ONE. 2020;15(11): e0242169.

pubmed: 33180816 pmcid: 7660513 doi: 10.1371/journal.pone.0242169

Morlion BJ, Mueller-Lissner SA, Vellucci R, Leppert W, Coffin BC, Dickerson SL, et al. Oral prolonged-release oxycodone/naloxone for managing pain and opioid-induced constipation: a review of the evidence. Pain Pract. 2018;18(5):647–65.

pubmed: 28944983 doi: 10.1111/papr.12646

Colucci SV, Perrino PJ, Shram M, Bartlett C, Wang Y, Harris SC. Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users. Clin Drug Investig. 2014;34(6):421–9.

pubmed: 24756361 pmcid: 4026623 doi: 10.1007/s40261-014-0192-3

Walsh SL, Nuzzo PA, Babalonis S, Casselton V, Lofwall MR. Intranasal buprenorphine alone and in combination with naloxone: abuse liability and reinforcing efficacy in physically dependent opioid abusers. Drug Alcohol Depend. 2016;162:190–8.

pubmed: 27012435 pmcid: 4833536 doi: 10.1016/j.drugalcdep.2016.03.005

Naloxone. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Naloxone#section=3D-Conformer . Accessed Oct 26 2022.

Hansch C, Hoekman D, Leo A, Zhang L, Li P. The expanding role of quantitative structure-activity relationships (QSAR) in toxicology. Toxicol Lett. 1995;79:45–53. https://doi.org/10.1016/0378-4274(95)03356-p .

doi: 10.1016/0378-4274(95)03356-p pubmed: 7570673

Balyan R, Hahn D, Huang H, Chidambaran V. Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic. Expert Opin Drug Metab Toxicol. 2020;16(2):125–41.

pubmed: 31976778 pmcid: 7199505 doi: 10.1080/17425255.2020.1721458

Tam SW. (+)-[3H]SKF 10,047, (+)-[3H]ethylketocyclazocine, mu, kappa, delta and phencyclidine binding sites in guinea pig brain membranes. Eur J Pharmacol. 1985;109(1):33–41.

pubmed: 2986989 doi: 10.1016/0014-2999(85)90536-9

Kanemasa T, Koike K, Takase K, Arai T, Nakamura A, Morioka Y, et al. Pharmacological profile of naldemedine, a peripherally acting μ-opioid receptor antagonist: comparison with naloxone and naloxegol. J Pharmacol Exp Ther. 2020;373(3):438–44.

pubmed: 32169839 doi: 10.1124/jpet.119.264515

Moss RB, Pryor MM, Baillie R, Kudrycki K, Friedrich C, Reed M, et al. Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level. PLoS ONE. 2020;15(6): e0234683.

pubmed: 32544184 pmcid: 7297366 doi: 10.1371/journal.pone.0234683

Cassel JA, Daubert JD, DeHaven RN. [(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol. 2005;520(1–3):29–36.

pubmed: 16165125 doi: 10.1016/j.ejphar.2005.08.008

Melichar JK, Nutt DJ, Malizia AL. Naloxone displacement at opioid receptor sites measured in vivo in the human brain. Eur J Pharmacol. 2003;459(2–3):217–9.

pubmed: 12524149 doi: 10.1016/S0014-2999(02)02872-8

Glass PS, Jhaveri RM, Smith LR. Comparison of potency and duration of action of nalmefene and naloxone. Anesth Analg. 1994;78(3):536–41.

pubmed: 8109774 doi: 10.1213/00000539-199403000-00021

Kim HK, Nelson LS. Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Opin Drug Saf. 2015;14(7):1137–46.

pubmed: 25865597 doi: 10.1517/14740338.2015.1037274

Trøstheim M, Eikemo M, Haaker J, Frost JJ, Leknes S. Opioid antagonism in humans: a primer on optimal dose and timing for central mu-opioid receptor blockade. Neuropsychopharmacology. 2023;48(2):299–307.

pubmed: 35978096 doi: 10.1038/s41386-022-01416-z

Frost JJ, Wagner HN Jr, Dannals RF, Ravert HT, Links JM, Wilson AA, et al. Imaging opiate receptors in the human brain by positron tomography. J Comput Assist Tomogr. 1985;9(2):231–6.

pubmed: 2982931 doi: 10.1097/00004728-198503000-00001

Sadzot B, Mayberg HS, Frost JJ. Imaging opiate receptors in the human brain with positron emission tomography. Potential applications for drug addiction research. Acta Psychiatr Belg. 1990;90(1):9–19.

pubmed: 1670391

Kim S, Wagner HN Jr, Villemagne VL, Kao PF, Dannals RF, Ravert HT, et al. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. J Nucl Med. 1997;38(11):1726–31.

pubmed: 9374341

Villemagne VL, Frost JJ, Dannals RF, Lever JR, Tanada S, Natarajan TK, et al. Comparison of [11C]diprenorphine and [11C]carfentanil in vivo binding to opiate receptors in man using a dual detector system. Eur J Pharmacol. 1994;257(1–2):195–7.

pubmed: 7915990 doi: 10.1016/0014-2999(94)90712-9

Johansson J, Hirvonen J, Lovro Z, Ekblad L, Kaasinen V, Rajasilta O, et al. Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects. Neuropsychopharmacology. 2019;44(9):1667–73.

pubmed: 30867551 pmcid: 6785104 doi: 10.1038/s41386-019-0368-x

Bice AN, Wagner HN Jr, Frost JJ, Natarajan TK, Lee MC, Wong DF, et al. Simplified detection system for neuroreceptor studies in the human brain. J Nucl Med. 1986;27(2):184–91.

pubmed: 3012020

Tylleskar I, Skulberg AK, Nilsen T, Skarra S, Jansook P, Dale O. Pharmacokinetics of a new, nasal formulation of naloxone. Eur J Clin Pharmacol. 2017;73(5):555–62.

pubmed: 28144724 doi: 10.1007/s00228-016-2191-1

Zuurmond WW, Meert TF, Noorduin H. Partial versus full agonists for opioid-mediated analgesia—focus on fentanyl and buprenorphine. Acta Anaesthesiol Belg. 2002;53(3):193–201.

pubmed: 12461829

Fishman J, Roffwarg H, Hellman L. Disposition of naloxone-7,8,3H in normal and narcotic-dependent men. J Pharmacol Exp Ther. 1973;187(3):575–80.

pubmed: 4588968

Fujimoto JM. Isolation of naloxone-3-glucuronide from human urine. Proc Soc Exp Biol Med. 1970;133(1):317–9.

pubmed: 5412354 doi: 10.3181/00379727-133-34465

Weinstein SH, Pfeffer M, Schor JM. Metabolism and pharmacokinetics of naloxone. Adv Biochem Psychopharmacol. 1973;8:525–35.

pubmed: 4794980

Papathanasiou T, Springborg AD, Kongstad KT, Staerk D, Moller K, Taylor BK, et al. High-dose naloxone, an experimental tool uncovering latent sensitisation: pharmacokinetics in humans. Br J Anaesth. 2019;123(2):e204–14.

pubmed: 30915992 pmcid: 6676012 doi: 10.1016/j.bja.2018.12.007

Tylleskar I, Skarra S, Skulberg AK, Dale O. The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers. Eur J Clin Pharmacol. 2021;77(12):1901–8.

pubmed: 34327552 pmcid: 8585821 doi: 10.1007/s00228-021-03190-1

Dale O, Nilsen T, Loftsson T, Hjorth Tonnesen H, Klepstad P, Kaasa S, et al. Intranasal midazolam: a comparison of two delivery devices in human volunteers. J Pharm Pharmacol. 2006;58(10):1311–8.

pubmed: 17034653 doi: 10.1211/jpp.58.10.0003

Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther. 2012;50(5):360–7.

pubmed: 22541841 doi: 10.5414/CP201646

Alqurshi A, Kumar Z, McDonald R, Strang J, Buanz A, Ahmed S, et al. Amorphous formulation and in vitro performance testing of instantly disintegrating buccal tablets for the emergency delivery of naloxone. Mol Pharm. 2016;13(5):1688–98.

pubmed: 26977787 doi: 10.1021/acs.molpharmaceut.6b00096

Berkowitz BA. The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet. 1976;1(3):219–30.

pubmed: 13957 doi: 10.2165/00003088-197601030-00004

Ngai SH, Berkowitz BA, Yang JC, Hempstead J, Spector S. Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. Anesthesiology. 1976;44(5):398–401.

pubmed: 1267205 doi: 10.1097/00000542-197605000-00008

Berkowitz BA, Ngai SH, Hempstead J, Spector S. Disposition of naloxone: use of a new radioimmunoassay. J Pharmacol Exp Ther. 1975;195(3):499–504.

pubmed: 1195133

Albeck H, Woodfield S, Kreek MJ. Quantitative and pharmacokinetic analysis of naloxone in plasma using high-performance liquid chromatography with electrochemical detection and solid-phase extraction. J Chromatogr. 1989;488(2):435–45.

pubmed: 2745633 doi: 10.1016/S0378-4347(00)82967-9

Tylleskar I, Skulberg AK, Nilsen T, Skarra S, Dale O. Naloxone nasal spray—bioavailability and absorption pattern in a phase 1 study. Tidsskr Nor Laegeforen. 2019. https://doi.org/10.4045/tidsskr.19.0162 .

doi: 10.4045/tidsskr.19.0162 pubmed: 31556537

Tylleskar I, Skulberg AK, Skarra S, Nilsen T, Dale O. Pharmacodynamics and arteriovenous difference of intravenous naloxone in healthy volunteers exposed to remifentanil. Eur J Clin Pharmacol. 2018;74(12):1547–53.

pubmed: 30143830 doi: 10.1007/s00228-018-2545-y

Gufford BT, Ainslie GR, White JR Jr, Layton ME, Padowski JM, Pollack GM, et al. Comparison of a new intranasal naloxone formulation to intramuscular naloxone: results from hypothesis-generating small clinical studies. Clin Transl Sci. 2017;10(5):380–6.

pubmed: 28504483 pmcid: 5593165 doi: 10.1111/cts.12473

Lewis JM, Klein-Schwartz W, Benson BE, Oderda GM, Takai S. Continuous naloxone infusion in pediatric narcotic overdose. Am J Dis Child. 1984;138(10):944–6.

pubmed: 6475855

Gourlay GK, Coulthard K. The role of naloxone infusions in the treatment of overdoses of long half-life narcotic agonists: application to nor-methadone. Br J Clin Pharmacol. 1983;15(2):269–71.

pubmed: 6849762 pmcid: 1427850 doi: 10.1111/j.1365-2125.1983.tb01498.x

Waldron VD, Klimt CR, Seibel JE. Methadone overdose treated with naloxone infusion. JAMA. 1973;225(1):53.

pubmed: 4740306 doi: 10.1001/jama.1973.03220280041012

Bradberry JC, Raebel MA. Continuous infusion of naloxone in the treatment of narcotic overdose. Drug Intell Clin Pharm. 1981;15(12):945–50.

pubmed: 7338189

Goldfrank L, Weisman RS, Errick JK, Lo MW. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med. 1986;15(5):566–70.

pubmed: 3963538 doi: 10.1016/S0196-0644(86)80994-5

Mann J, Samieegohar M, Chaturbedi A, Zirkle J, Han X, Ahmadi SF, et al. Development of a translational model to assess the impact of opioid overdose and naloxone dosing on respiratory depression and cardiac arrest. Clin Pharmacol Ther. 2022;112(5):1020–32.

pubmed: 35766413 doi: 10.1002/cpt.2696

Takahashi M, Sugiyama K, Hori M, Chiba S, Kusaka K. Naloxone reversal of opioid anesthesia revisited: clinical evaluation and plasma concentration analysis of continuous naloxone infusion after anesthesia with high-dose fentanyl. J Anesth. 2004;18(1):1–8.

pubmed: 14991468 doi: 10.1007/s00540-003-0214-4

Barton ED, Colwell CB, Wolfe T, Fosnocht D, Gravitz C, Bryan T, et al. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J Emerg Med. 2005;29(3):265–71.

pubmed: 16183444 doi: 10.1016/j.jemermed.2005.03.007

Skulberg AK, Tylleskar I, Valberg M, Braarud AC, Dale J, Heyerdahl F, et al. Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double-dummy, randomised, controlled trial. Addiction. 2022;117(6):1658–67.

pubmed: 35137493 pmcid: 9302677 doi: 10.1111/add.15806

Tsekouras AA, Macheras P. Re-examining naloxone pharmacokinetics after intranasal and intramuscular administration using the finite absorption time concept. Eur J Drug Metab Pharmacokinet. 2023;48(4):455–62.

pubmed: 37266859 doi: 10.1007/s13318-023-00831-x

Robertson TM, Hendey GW, Stroh G, Shalit M. Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehosp Emerg Care. 2009;13(4):512–5.

pubmed: 19731165 doi: 10.1080/10903120903144866

Skulberg AK, Tylleskar I, Nilsen T, Skarra S, Salvesen O, Sand T, et al. Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers. Eur J Clin Pharmacol. 2018;74(7):873–83.

pubmed: 29568976 doi: 10.1007/s00228-018-2443-3

Skulberg AK, Asberg A, Khiabani HZ, Rostad H, Tylleskar I, Dale O. Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial. Addiction. 2019;114(5):859–67.

pubmed: 30644628 doi: 10.1111/add.14552

Vanky E, Hellmundt L, Bondesson U, Eksborg S, Lundeberg S. Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. Acta Anaesthesiol Scand. 2017;61(6):636–40.

pubmed: 28444856 doi: 10.1111/aas.12898

Malmros Olsson E, Lönnqvist PA, Stiller CO, Eksborg S, Lundeberg S. Rapid systemic uptake of naloxone after intranasal administration in children. Paediatr Anaesth. 2021;31(6):631–6.

pubmed: 33687794 doi: 10.1111/pan.14175

Lapidot T, Bouhajib M, Faulknor J, Khan S, Krayz GT, Abrutzky C, et al. A novel faster-acting, dry powder-based, naloxone intranasal formulation for opioid overdose. Pharm Res. 2022;39(5):963–75.

pubmed: 35386013 pmcid: 9160115 doi: 10.1007/s11095-022-03247-5

Middleton LS, Nuzzo PA, Lofwall MR, Moody DE, Walsh SL. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction. 2011;106(8):1460–73.

pubmed: 21395892 pmcid: 3776483 doi: 10.1111/j.1360-0443.2011.03424.x

Lai D, Pham AT, Nekkar Rao PP, Beazely MA. The effects of heat and freeze-thaw cycling on naloxone stability. Harm Reduct J. 2019;16(1):17.

pubmed: 30813917 pmcid: 6391798 doi: 10.1186/s12954-019-0288-4

McDonald R, Lorch U, Woodward J, Bosse B, Dooner H, Mundin G, et al. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: phase I healthy volunteer study. Addiction. 2018;113(3):484–93.

pubmed: 29143400 doi: 10.1111/add.14033

Edwards ET, Edwards ES, Davis E, Mulcare M, Wiklund M, Kelley G. Comparative usability study of a novel auto-injector and an intranasal system for naloxone delivery. Pain Ther. 2015;4(1):89–105.

pubmed: 25910473 pmcid: 4470965 doi: 10.1007/s40122-015-0035-9

Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacomet Syst Pharmacol. 2012;1: e6.

doi: 10.1038/psp.2012.4

Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacomet Syst Pharmacol. 2013;2: e38.

doi: 10.1038/psp.2013.14

Upton RN, Mould DR. Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods. CPT Pharmacomet Syst Pharmacol. 2014;3: e88.

doi: 10.1038/psp.2013.71

Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit. 2008;30(4):490–6.

pubmed: 18641540 doi: 10.1097/FTD.0b013e3181816214

Algera MH, Kamp J, van der Schrier R, van Velzen M, Niesters M, Aarts L, et al. Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal. Br J Anaesth. 2019;122(6):e168–79.

pubmed: 30915997 doi: 10.1016/j.bja.2018.12.023

Olofsen E, Mooren R, van Dorp E, Aarts L, Smith T, den Hartigh J, et al. Arterial and venous pharmacokinetics of morphine-6-glucuronide and impact of sample site on pharmacodynamic parameter estimates. Anesth Analg. 2010;111(3):626–32.

pubmed: 20547824 doi: 10.1213/ANE.0b013e3181e5e8af

Loimer N, Hofmann P, Chaudhry HR. Nasal administration of naloxone for detection of opiate dependence. J Psychiatr Res. 1992;26(1):39–43.

pubmed: 1560408 doi: 10.1016/0022-3956(92)90014-F

Ravnborg M, Jensen FM, Jensen NH, Holk IK. Pupillary diameter and ventilatory CO

pubmed: 3113290 doi: 10.1213/00000539-198709000-00007

Friedman MS, Manini AF. Validation of criteria to guide prehospital naloxone administration for drug-related altered mental status. J Med Toxicol. 2016;12(3):270–5.

pubmed: 27083903 pmcid: 4996789 doi: 10.1007/s13181-016-0549-5

Loimer N, Hofmann P, Chaudhry HR. Nasal administration of naloxone is as effective as the intravenous route in opiate addicts. Int J Addict. 1994;29(6):819–27.

pubmed: 8034388 doi: 10.3109/10826089409047912

Scott JC, Ponganis KV, Stanski DR. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 1985;62(3):234–41.

pubmed: 3919613 doi: 10.1097/00000542-198503000-00005

Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH. Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharmacol. 2006;1(1):109–18.

pubmed: 18666382 doi: 10.2174/157488406775268219

Gottås A, Øiestad EL, Boix F, Vindenes V, Ripel Å, Thaulow CH, et al. Levels of heroin and its metabolites in blood and brain extracellular fluid after i.v. heroin administration to freely moving rats. Br J Pharmacol. 2013;170(3):546–56.

pubmed: 23865556 pmcid: 3791993 doi: 10.1111/bph.12305

Kiyatkin EA. Respiratory depression and brain hypoxia induced by opioid drugs: morphine, oxycodone, heroin, and fentanyl. Neuropharmacology. 2019;151:219–26.

pubmed: 30735692 pmcid: 6500744 doi: 10.1016/j.neuropharm.2019.02.008

Darke S, Duflou J. The toxicology of heroin-related death: estimating survival times. Addiction. 2016;111(9):1607–13.

pubmed: 27082514 doi: 10.1111/add.13429

Poklis J, Poklis A, Wolf C, Mainland M, Hair L, Devers K, et al. Postmortem tissue distribution of acetyl fentanyl, fentanyl and their respective nor-metabolites analyzed by ultrahigh performance liquid chromatography with tandem mass spectrometry. Forensic Sci Int. 2015;257:435–41.

pubmed: 26583960 pmcid: 4879818 doi: 10.1016/j.forsciint.2015.10.021

Burns G, DeRienz RT, Baker DD, Casavant M, Spiller HA. Could chest wall rigidity be a factor in rapid death from illicit fentanyl abuse? Clin Toxicol. 2016;54(5):420–3.

doi: 10.3109/15563650.2016.1157722

Kelly E, Sutcliffe K, Cavallo D, Ramos-Gonzalez N, Alhosan N, Henderson G. The anomalous pharmacology of fentanyl. Br J Pharmacol. 2021;180:797–812.

pubmed: 34030211 doi: 10.1111/bph.15573

Sutcliffe KJ, Corey RA, Alhosan N, Cavallo D, Groom S, Santiago M, et al. Interaction with the lipid membrane influences fentanyl pharmacology. Adv Drug Alcohol Res. 2022. https://doi.org/10.3389/adar.2022.10280 .

doi: 10.3389/adar.2022.10280 pubmed: 35909438 pmcid: 7613138

Hill R, Santhakumar R, Dewey W, Kelly E, Henderson G. Fentanyl depression of respiration: comparison with heroin and morphine. Br J Pharmacol. 2020;177(2):254–66.

pubmed: 31499594 doi: 10.1111/bph.14860

Coruh B, Tonelli MR, Park DR. Fentanyl-induced chest wall rigidity. Chest. 2013;143(4):1145–6.

pubmed: 23546488 doi: 10.1378/chest.12-2131

Miner NB, Schutzer WE, Zarnegarnia Y, Janowsky A, Torralva R. Fentanyl causes naloxone-resistant vocal cord closure: a platform for testing opioid overdose treatments. Drug Alcohol Depend. 2021;227: 108974.

pubmed: 34492557 doi: 10.1016/j.drugalcdep.2021.108974

Torralva R, Janowsky A. Noradrenergic mechanisms in fentanyl-mediated rapid death explain failure of naloxone in the opioid crisis. J Pharmacol Exp Ther. 2019;371(2):453–75.

pubmed: 31492824 pmcid: 6863461 doi: 10.1124/jpet.119.258566

Saari T, Tylleskär I, Skulberg A, Dale O. Population pharmacokinetic analysis of extravascular naloxone administration in healthy volunteers. Anesthesiology. 2024.

World Health Organization, Management of Substance Abuse Team. Community management of opioid overdose. Geneva: World Health Organization; 2014.

Tylleskar I, Gjersing L, Bjornsen LP, Braarud AC, Heyerdahl F, Dale O, et al. Prehospital naloxone administration—what influences choice of dose and route of administration? BMC Emerg Med. 2020;20(1):71.

pubmed: 32891142 pmcid: 7487505 doi: 10.1186/s12873-020-00366-3

Neale J, Strang J. Naloxone—does over-antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin/opioid overdose. Addiction. 2015;110(10):1644–52.

pubmed: 26119038 doi: 10.1111/add.13027

Buajordet I, Naess AC, Jacobsen D, Brors O. Adverse events after naloxone treatment of episodes of suspected acute opioid overdose. Eur J Emerg Med. 2004;11(1):19–23.

pubmed: 15167188 doi: 10.1097/00063110-200402000-00004

Krotulski AJ, Chapman BP, Marks SJ, Ontiveros ST, Devin-Holcombe K, Fogarty MF, et al. Sentanyl: a comparison of blood fentanyl concentrations and naloxone dosing after non-fatal overdose. Clin Toxicol. 2022;60(2):197–204.

doi: 10.1080/15563650.2021.1948558

Lee D, Chronister CW, Broussard WA, Utley-Bobak SR, Schultz DL, Vega RS, et al. Illicit fentanyl-related fatalities in Florida: toxicological findings. J Anal Toxicol. 2016;40(8):588–94.

pubmed: 27702938 doi: 10.1093/jat/bkw087

Fogarty MF, Papsun DM, Logan BK. Analysis of fentanyl and 18 novel fentanyl analogs and metabolites by lc-ms-ms, and report of fatalities associated with methoxyacetylfentanyl and cyclopropylfentanyl. J Anal Toxicol. 2018;42(9):592–604.

pubmed: 29750250 doi: 10.1093/jat/bky035

Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(2):146–55.

pubmed: 22784117 pmcid: 3739053 doi: 10.1056/NEJMra1202561

Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–67.

pubmed: 13679531 doi: 10.1056/NEJMra035092

Moe-Byrne T, Brown JVE, McGuire W. Naloxone for opioid-exposed newborn infants. Cochrane Database Syst Rev. 2018;10(10):cd003483.

pubmed: 30311212

Brennscheidt U, Brunnmüller U, Proppe D, Thomann P, Seiler KU. Pharmacokinetics of tilidine and naloxone in patients with severe hepatic impairment. Arzneimittelforschung. 2007;57(2):106–11.

pubmed: 17396621

Cohen MR, Cohen RM, Pickar D, Murphy DL, Bunney WE Jr. Physiological effects of high dose naloxone administration to normal adults. Life Sci. 1982;30(23):2025–31.

pubmed: 6287138 doi: 10.1016/0024-3205(82)90443-X

Cohen MR, Cohen RM, Pickar D, Weingartner H, Murphy DL, Bunney WE Jr. Behavioural effects after high dose naloxone administration to normal volunteers. Lancet. 1981;2(8255):1110.

pubmed: 6118553 doi: 10.1016/S0140-6736(81)91308-8

McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016;111(7):1177–87.

pubmed: 27028542 pmcid: 5071734 doi: 10.1111/add.13326

Razaghizad A, Windle SB, Filion KB, Gore G, Kudrina I, Paraskevopoulos E, et al. The effect of overdose education and naloxone distribution: an umbrella review of systematic reviews. Am J Public Health. 2021;111(8):e1–12.

pubmed: 34214412 pmcid: 8489614 doi: 10.2105/AJPH.2021.306306

Clarke SF, Dargan PI, Jones AL. Naloxone in opioid poisoning: walking the tightrope. Emerg Med J. 2005;22(9):612–6.

pubmed: 16113176 pmcid: 1726910 doi: 10.1136/emj.2003.009613

Wermeling DP. Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access. Ther Adv Drug Saf. 2015;6(1):20–31.

pubmed: 25642320 pmcid: 4308412 doi: 10.1177/2042098614564776

Strang J, Neale J, McDonald R, Kalk N. Toxicity: exploring and expanding the concept. Addiction. 2018;113(4):592–4.

pubmed: 29205614 doi: 10.1111/add.14080

Johnson C, Mayer P, Grosz D. Pulmonary edema following naloxone administration in a healthy orthopedic patient. J Clin Anesth. 1995;7(4):356–7.

pubmed: 7546765 doi: 10.1016/0952-8180(95)00038-J

Prough DS, Roy R, Bumgarner J, Shannon G. Acute pulmonary edema in healthy teenagers following conservative doses of intravenous naloxone. Anesthesiology. 1984;60(5):485–6.

pubmed: 6711858 doi: 10.1097/00000542-198405000-00018

Grout S, Dave M, Lefort R. Naloxone-associated pulmonary edema in a 3-year-old with opioid overdose. J Am Coll Emerg Phys Open. 2022;3(3): e12740.

Kummer RL, Kempainen RR, Olives TD, Leatherman JW, Prekker ME. Naloxone-associated pulmonary edema following recreational opioid overdose. Am J Emerg Med. 2022;53:41–3.

pubmed: 34973491 doi: 10.1016/j.ajem.2021.12.030

Elkattawy S, Alyacoub R, Ejikeme C, Noori MAM, Remolina C. Naloxone induced pulmonary edema. J Commun Hosp Intern Med Perspect. 2021;11(1):139–42.

doi: 10.1080/20009666.2020.1854417

Farkas A, Lynch MJ, Westover R, Giles J, Siripong N, Nalatwad A, et al. Pulmonary complications of opioid overdose treated with naloxone. Ann Emerg Med. 2020;75(1):39–48.

pubmed: 31182316 doi: 10.1016/j.annemergmed.2019.04.006

Kienbaum P, Thürauf N, Michel MC, Scherbaum N, Gastpar M, Peters J. Profound increase in epinephrine concentration in plasma and cardiovascular stimulation after mu-opioid receptor blockade in opioid-addicted patients during barbiturate-induced anesthesia for acute detoxification. Anesthesiology. 1998;88(5):1154–61.

pubmed: 9605673 doi: 10.1097/00000542-199805000-00004

Tigerstedt I, Tammisto T. Effect of naloxone reversal on CO

pubmed: 654855 doi: 10.1111/j.1399-6576.1978.tb01293.x

Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018;9(1):63–88.

pubmed: 29318006 doi: 10.1177/2042098617744161

Gaddis GM, Watson WA. Naloxone-associated patient violence: an overlooked toxicity? Ann Pharmacother. 1992;26(2):196–8.

pubmed: 1554930 doi: 10.1177/106002809202600211

Avetian GK, Fiuty P, Mazzella S, Koppa D, Heye V, Hebbar P. Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations. Curr Med Res Opin. 2018;34(4):573–6.

pubmed: 28535115 doi: 10.1080/03007995.2017.1334637

Thompson J, Salter J, Bui P, Herbert L, Mills D, Wagner D, et al. Safety, efficacy, and cost of 0.4-mg versus 2-mg intranasal naloxone for treatment of prehospital opioid overdose. Ann Pharmacother. 2022;56(3):285–9.

pubmed: 34229467 doi: 10.1177/10600280211030918

Moustaqim-Barrette A, Papamihali K, Williams S, Ferguson M, Moe J, Purssell R, et al. Adverse events related to bystander naloxone administration in cases of suspected opioid overdose in British Columbia: an observational study. PLoS ONE. 2021;16(10): e0259126.

pubmed: 34714854 pmcid: 8555799 doi: 10.1371/journal.pone.0259126

Isoardi KZ, Parker L, Harris K, Rashford S, Isbister GK. Acute opioid withdrawal following intramuscular administration of naloxone 1.6 mg: a prospective out-of-hospital series. Ann Emerg Med. 2022;80(2):120–6.

pubmed: 35491292 doi: 10.1016/j.annemergmed.2022.03.004

Wightman RS, Nelson LS. Naloxone dosing in the era of fentanyl: the path widens by traveling down it. Ann Emerg Med. 2022;80(2):127–9.

pubmed: 35643776 doi: 10.1016/j.annemergmed.2022.04.014

Moe J, Godwin J, Purssell R, O’Sullivan F, Hau JP, Purssell E, et al. Naloxone dosing in the era of ultra-potent opioid overdoses: a systematic review. CJEM. 2020;22(2):178–86.

pubmed: 31955714 doi: 10.1017/cem.2019.471

Gooley B, Weston B, Colella MR, Farkas A. Outcomes of law enforcement officer administered naloxone. Am J Emerg Med. 2022;62:25–9.

pubmed: 36215781 doi: 10.1016/j.ajem.2022.09.041

Lemen PM, Garrett DP, Thompson E, Aho M, Vasquez C, Park JN. High-dose naloxone formulations are not as essential as we thought. medRxiv. 2023;6:63.

Vilke GM, Sloane C, Smith AM, Chan TC. Assessment for deaths in out-of-hospital heroin overdose patients treated with naloxone who refuse transport. Acad Emerg Med. 2003;10(8):893–6.

pubmed: 12896894

Rudolph SS, Jehu G, Nielsen SL, Nielsen K, Siersma V, Rasmussen LS. Prehospital treatment of opioid overdose in Copenhagen—is it safe to discharge on-scene? Resuscitation. 2011;82(11):1414–8.

pubmed: 21745532 doi: 10.1016/j.resuscitation.2011.06.027

Wampler DA, Molina DK, McManus J, Laws P, Manifold CA. No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose. Prehosp Emerg Care. 2011;15(3):320–4.

pubmed: 21612385 doi: 10.3109/10903127.2011.569854

Watson WA, Steele MT, Muelleman RL, Rush MD. Opioid toxicity recurrence after an initial response to naloxone. J Toxicol Clin Toxicol. 1998;36(1–2):11–7.

pubmed: 9541035 doi: 10.3109/15563659809162577

Boyd JJ, Kuisma MJ, Alaspaa AO, Vuori E, Repo JV, Randell TT. Recurrent opioid toxicity after pre-hospital care of presumed heroin overdose patients. Acta Anaesthesiol Scand. 2006;50(10):1266–70.

pubmed: 17067327 doi: 10.1111/j.1399-6576.2006.01172.x

Sutter ME, Gerona RR, Davis MT, Roche BM, Colby DK, Chenoweth JA, et al. Fatal fentanyl: one pill can kill. Acad Emerg Med. 2017;24(1):106–13.

pubmed: 27322591 doi: 10.1111/acem.13034

Sabzghabaee AM, Eizadi-Mood N, Yaraghi A, Zandifar S. Naloxone therapy in opioid overdose patients: intranasal or intravenous? A randomized clinical trial. Arch Med Sci. 2014;10(2):309–14.

pubmed: 24904666 pmcid: 4042052 doi: 10.5114/aoms.2014.42584

Kelly AM, Kerr D, Dietze P, Patrick I, Walker T, Koutsogiannis Z. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust. 2005;182(1):24–7.

pubmed: 15651944 doi: 10.5694/j.1326-5377.2005.tb06550.x

Kerr D, Kelly AM, Dietze P, Jolley D, Barger B. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction. 2009;104(12):2067–74.

pubmed: 19922572 doi: 10.1111/j.1360-0443.2009.02724.x

Dietze P, Jauncey M, Salmon A, Mohebbi M, Latimer J, van Beek I, et al. Effect of intranasal vs intramuscular naloxone on opioid overdose: a randomized clinical trial. JAMA Netw Open. 2019;2(11): e1914977.

pubmed: 31722024 pmcid: 6902775 doi: 10.1001/jamanetworkopen.2019.14977

World Health Organization. WHO guidelines approved by the guidelines. Review committee community management of opioid overdose. Geneva: World Health Organization; 2014.

Madah-Amiri D, Clausen T, Lobmaier P. Rapid widespread distribution of intranasal naloxone for overdose prevention. Drug Alcohol Depend. 2017;173:17–23.

pubmed: 28182982 doi: 10.1016/j.drugalcdep.2016.12.013

Raman R. High-potency benzodiazepine misuse in opioid-dependent patients: use naloxone with care. Emerg Med J. 2023;40(3):224–7.

pubmed: 35977818 doi: 10.1136/emermed-2021-212254

Skulberg AK, Tylleskar I, Dale O. Naloxone administration—no balance without titration. Addiction. 2022;117:2750–1.

pubmed: 35589622 doi: 10.1111/add.15947

Madah-Amiri D, Skulberg AK, Braarud AC, Dale O, Heyerdahl F, Lobmaier P, et al. Ambulance-attended opioid overdoses: an examination into overdose locations and the role of a safe injection facility. Subst Abus. 2019;40(3):383–8.

pubmed: 29949448 doi: 10.1080/08897077.2018.1485130

Yugar B, McManus K, Ramdin C, Nelson LS, Parris MA. Systematic review of naloxone dosing and adverse events in the emergency department. J Emerg Med. 2023;65(3):e188–98.

pubmed: 37652808 doi: 10.1016/j.jemermed.2023.05.006

Clinical Pharmacokinetics and Pharmacodynamics of Naloxone.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Teijo I Saari (TI)

John Strang (J)

Ola Dale (O)

Classifications MeSH